Received Jan 27, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
had a negative titer; This spontaneous report was received from a pharmacist and refers to a 23-year-old male patient. The patient's concurrent conditions included Multiple Sclerosis (MS). His medical history, previous drug reactions, drug allergies and concomitant therapies were unknown by the reporter. On an unspecified date, the patient was appropriately dosed with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) during his childhood vaccination schedule (strength, dose, frequency, route of administration, lot #, and expiration date were not provided) reconstituted with a sterile diluent, as prophylaxis. On an unspecified date, the patient had a negative titer (Antibody test negative). They wanted to start the patient on an unspecified medication for MS and wanted to ensure he was appropriately vaccinated prior to starting due to its ability to cause immunocompetence. At the reporting time, the outcome of the event was unknown. The causal relationship between the event and Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) was not provided.
MS